Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, Ontario, Canada

Dr. Peter Lin began his studies in the Faculty of Science and Engineering at the University of Toronto in Toronto, Ontario. Midway through, he moved to the Faculty of Medicine, where he completed his studies and became involved in research. Over the years, it became apparent to him that there was a wide chasm between research and clinical practice, and he moved into clinical practice in primary care and eventually into teaching in order to help bridge this gap. He served as the medical director at the Health & Wellness Centre, University of Toronto Scarborough, for 7 years.

Currently, Dr. Peter Lin is the Director of Primary Care Initiatives at the Canadian Heart Research Centre. He is also a contributing author to the Canadian Diabetes Guidelines 2013 and 2018 on the vascular protection section. He is also Associate Editor for the Elsevier WebPortal - PracticeUpdate Primary Care. He lectures and speaks internationally on a variety of topics. Dr. Lin has worked with KDIGO in order to help improve care for CKD patients. He has also been tracking and providing information on COVID-19 to the public since the beginning of the pandemic. Dr. Lin received a teaching award from the College of Family Physicians in 2011.

Disclosures

Dr. Lin has consulted with the following companies on Continuing Medical Education programs:

Astrazeneca, Boeringher Ingelheim, Bayer, Eli Lilly, Amgen, Janssen, Merck, Pfizer, Sanofi, Abbott, HLS Therapeutics Inc.

No clinical trials. No patents.

Recent Contributions to PracticeUpdate:

  1. NT-proBNP and Cardiovascular Event Risk in Individuals With Prediabetes Undergoing Cardiovascular Evaluation
  2. Intensive Statin Therapy vs Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome
  3. Calcium Channel Blocker Use and Associated Glaucoma and Related Traits Among UK Biobank Participants
  4. Pillars of Therapy to Slow Diabetic Nephropathy Progression
  5. Estimated Lifetime Gained With Cancer Screening Tests
  6. Prevalence and Predictors of Primary Nonadherence to Medications Prescribed in Primary Care
  7. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas in Reducing the Risk of Major Adverse Cardiovascular Events
  8. Dupilumab for Patients With COPD With Type 2 Inflammation Indicated by Eosinophil Counts
  9. Association of Exposure to Extreme Temperature Events and Fine Particulate Matter With Myocardial Infarction–Related Mortality
  10. Association Between Serum 25-Hydroxyvitamin D Levels and the Risk of Colorectal Cancer

Most Read This Week

Recently Updated